AFAntonio Fioravanti

Antonio Fioravanti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Antonio Fioravanti has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Modified Sparing Binostril Endoscopic Endonasal Approach Combined With an Algorithm-Based Reconstruction Strategy: Surgical and Functional Outcomes in Sellar and Suprasellar Lesions

    by Carmine Antonio Donofrio, Giacomo Bertazzoni, Lucia Riccio, Marika Cominetti, Claudia Lodovica Modesti, Marco Faustini Fustini, Luca Pianta, Daniel Prevedello, Richard Shane Tubbs, Antonio Fioravanti

    BACKGROUND AND OBJECTIVES: Conventional binostril endoscopic endonasal approaches (EEAs) provide optimal surgical ergonomics but are often associated with sinonasal morbidity. Conversely, mononostril approaches preserve mucosal integrity at the expense of surgical maneuverability. We hypothesized that the modified sparing binostril approach (moSBA) may provide a favorable balance between surgical exposure, ergonomics, and sinonasal preservation while maintaining flexibility for risk-adapted reconstruction. This study evaluates the feasibility and functional outcomes of this technique combined with a risk-adapted skull base reconstruction strategy. METHODS: We retrospectively reviewed 81 patients who underwent EEA or extended EEA for sellar and suprasellar lesions between 2021 and 2025. All procedures were performed combining a paraseptal and a contralateral endonasal corridor (moSBA). The risk-adapted reconstructive algorithm included type 1 (hemostatic material with free mucosal graft), type 2 (inlay fat graft with onlay nasoseptal flap), and type 3 (modified gasket-seal). Outcomes included extent of resection, complications, and 22-item Sinonasal Outcome Test (SNOT-22) assessment. RESULTS: EEAs were performed in 56 (69.1%) and extended EEAs in 25 (30.9%) patients. Intraoperative cerebrospinal fluid (CSF) leakage occurred in 48 cases (59.3%) and was graded as 1 in 12.3%, 2 in 34.6%, and 3 in 12.3%. Reconstruction types 1, 2, and 3 were used in 40.7%, 46.9%, and 12.4% of cases, respectively. Gross total resection was achieved in 72.9%. Postoperative CSF leakage occurred in 2.5%. On exploratory multivariate analysis, reconstruction complexity was independently associated with higher postoperative SNOT-22 score (B = 3.379, 95% CI: 0.827-5.930, P = .010). CONCLUSION: The moSBA appears to be a feasible and safe option for selected sellar and suprasellar lesions, providing favorable surgical and functional outcomes in this single-center experience. Although higher reconstruction complexity was independently associated with higher postoperative SNOT-22 scores, residual confounding related to surgical invasiveness, skull base defect magnitude, and intraoperative CSF leakage severity cannot be excluded.


  • Open Access

    The Mastoid Foramen and Mastoid Emissary Vein Canal as Surgical Landmarks for Mastoid Pneumatization During Retrosigmoid Approach

    by Carmine Antonio Donofrio, Lucia Riccio, Filippo Badaloni, R. Shane Tubbs, Antonio Fioravanti

    BACKGROUND AND OBJECTIVES: The retrosigmoid approach (RSA) is a widely used technique for accessing the posterolateral skull base. Knowledge of anatomic landmarks remains crucial, particularly concerning the variability of temporal bone pneumatization. This study explores the anatomic, radiological, and intraoperative correlations between the mastoid foramen (MF), mastoid emissary vein canal (MEVC), and mastoid pneumatization during the RSA. METHODS: An anatomic analysis was performed on 2 dry temporal bones and 2 formalin-fixed specimens. The radiological study analyzed 100 patients' high-resolution computed tomography scans. Temporal bone pneumatization was graded using the Han classification. The MF was classified as “posterior” or “anterior” to the most posterior mastoid air cell (MAC); the MEVC was noted as “posterior to” or “within” the MACs. The mastoid foramen-mastoid air cell (MF-MAC) distance and minimal mastoid emissary vein canal-mastoid air cell (mMEVC-MAC) distance were defined as the gaps between the MF and MEVC and the most posterior MAC, respectively. The surgical study reviewed 54 patients undergoing RSA, for which we described the surgical technique and examined intraoperative and postoperative complications. RESULTS: Pneumatization grade inversely correlated with age ( P < .001). The MF and MEVC were posterior to MACs in 99.4% and 88.0% of cases, respectively. Higher pneumatization grades were significantly associated with shorter MF-MAC and mMEVC-MAC distances ( P < .001). A direct correlation was found between MF-MAC and mMEVC-MAC distances (r = 0.741, P < .001). Intraoperative MAC opening occurred in 5.6% of cases, all presenting Han grade 4 pneumatization and MEVC “within” MACs. No major intraoperative complications occurred, with only one case (1.9%) of cerebrospinal fluid wound leakage. CONCLUSION: The MF and MEVC serve as consistent and practical landmarks for predicting mastoid pneumatization and guiding RSA craniectomy. Preoperative radiological assessment enables targeted surgical planning to manage intraoperative opening of MACs.


  • Open Access

    Combined Endoscopic Endonasal Transclival and Contralateral Transmaxillary Approach to the Petrous Apex and the Petroclival Synchondrosis: Working “Around the Corner” of the Internal Carotid Artery—Quantitative Anatomical Study and Clinical Applications

    by Carmine Antonio Donofrio, Francesco Corrivetti, Lucia Riccio, Sergio Corvino, Iacopo Dallan, Antonio Fioravanti, Matteo de Notaris

    The endoscopic contralateral transmaxillary (CTM) approach has been proposed as a potential route to widen the corridor posterolateral to the internal carotid artery (ICA). In this study, we first refined the surgical technique of a combined multiportal endoscopic endonasal transclival (EETC) and CTM approach to the petrous apex (PA) and petroclival synchondrosis (PCS) in the dissection laboratory, and then validated its applications in a preliminary surgical series. The combined EETC and CTM approach was performed on three cadaver specimens based on four surgical steps: (1) the nasal, (2) the clival, (3) the maxillary and (4) the petrosal phases. The CTM provided a “head-on trajectory” to the PA and PCS and a short distance to the surgical field considerably furthering surgical maneuverability. The best operative set-up was achieved by introducing angled optics via the endonasal route and operative instruments via the transmaxillary corridor exploiting the advantages of a non-coaxial multiportal surgery. Clinical applications of the combined EETC and CTM approach were reported in three cases, a clival chordoma and two giant pituitary adenomas. The present translational study explores the safety and feasibility of a combined multiportal EETC and CTM approach to access the petroclival region though different corridors.


  • Open Access

    CD99 Expression and Prognostic Impact in Glioblastoma: A Single-Center Cohort Study

    by Andrea Rocca, Fabiola Giudici, Carmine Antonio Donofrio, Cristina Bottin, Maurizio Pinamonti, Benvenuto Ferrari, Francesco Schettini, Estela Pineda, Stefano Panni, Marika Cominetti, et al.

    Glioblastoma is the most frequent and aggressive brain tumor in adults. This study aims to evaluate the expression and prognostic impact of CD99, a membrane glycoprotein involved in cellular migration and invasion. In a cohort of patients with glioblastoma treated with surgery, radiotherapy and temozolomide, we retrospectively analyzed tumor expression of CD99 by immunohistochemistry (IHC) and by quantitative real-time polymerase chain reaction (qRT-PCR) for both the wild type (CD99wt) and the truncated (CD99sh) isoforms. The impact on overall survival (OS) was assessed with the Kaplan–Meier method and log-rank test and by multivariable Cox regression. Forty-six patients with glioblastoma entered this study. Immunohistochemical expression of CD99 was present in 83%. Only the CD99wt isoform was detected by qRT-PCR and was significantly correlated with CD99 expression evaluated by IHC (rho = 0.309, p = 0.037). CD99 expression was not associated with OS, regardless of the assessment methodology used (p = 0.61 for qRT-PCR and p = 0.73 for IHC). In an exploratory analysis of The Cancer Genome Atlas, casuistry of glioblastomas CD99 expression was not associated with OS nor with progression-free survival. This study confirms a high expression of CD99 in glioblastoma but does not show any significant impact on survival. Further preclinical studies are needed to define its role as a therapeutic target in glioblastoma.


  • Open Access

    Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report

    by Navid Sobhani, Victoria Bouchè, Giovanni Aldegheri, Andrea Rocca, Alberto D’angelo, Fabiola Giudici, Cristina Bottin, Carmine Antonio Donofrio, Maurizio Pinamonti, Benvenuto Ferrari, et al.

    With the advent of immunotherapies, the field of cancer therapy has been revived with new hope, especially for cancers with dismal prognoses, such as the glioblastoma multiforme (GBM). Currently, immunotherapies should potentiate the host’s own antitumor immune response against cancer cells, but it has been documented that they are effective only in small subsets of patients. Therefore, accurate predictors of response are urgently needed to identify who will benefit from immune-modulatory therapies. Brain tumors are challenging in terms of treatments. The immune response in the brain is highly regulated, and the immune microenvironment in brain metastases is active with a high density of tumor-infiltrating lymphocytes (TILs, CD3+ T cells) in certain patients and, therefore, may serve as a potential treatment target. In our study, we performed immunohistochemistry for CD3 and PD-L1 along the routine assessment of the O6-methylguanine-methyltransferase (MGMT) promoter methylation status and the IDH1 and 2 status in a single center cohort of 69 patients with GBM (58 primary tumors and 11 recurrences) who underwent standard multimodal therapies (surgery/radiotherapy/adjuvant temozolamide). We analyzed the association of PD-L1 tumor expression and TILs with overall survival (OS). The PD-L1 expression was observed in 25 of 58 (43%) newly diagnosed primary glioblastoma specimens. The sparse-to-moderate density of TILs, identified with CD3+ expression, was found in 48 of 58 (83%) specimens. Neither PD-L1 expression nor TILs were associated with overall survival. In conclusion, TILs and/or PD-L1 expression are detectable in the majority of glioblastoma samples, and even if they slightly relate to the outcome, they do not show a statistically significant correlation.